Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ubrogepant

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

- PMLiVE

Boehringer says Avastin biosimilar on track as Phase III gets underway

Clinical data suggests candidate has same biologic profile as Roche’s cancer drug

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Allergan buys two NASH drug developers in one day

More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics

- PMLiVE

A new era of collaboration

Looking at the factors driving this change and assessing the benefits

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links